Anthropic has reportedly walked away from talks to acquire Israeli AI startup Decart in a deal that had been valued at around $6 billion. The news, first reported by Silicon Republic, brings an abrupt end to what would have been one of the largest acquisitions in the AI sector to date. No official explanation for the breakdown has been offered by either company.
What We Know About the Deal's Collapse
Decart is an Israeli startup focused on high-speed AI inference, a capability that has drawn considerable attention as AI companies race to make their models faster and more cost-efficient. Anthropic had been eyeing the acquisition as a way to accelerate Claude's performance, with inference speed viewed as a key competitive differentiator going into 2025. The decision to walk away suggests either a valuation disagreement, strategic recalibration, or concerns that surfaced during due diligence.
Key Facts
- The reported acquisition price was approximately $6 billion
- Decart specializes in AI inference acceleration technology
- Anthropic has not publicly commented on the failed deal
- The talks had been ongoing for several weeks before collapsing
- Decart is headquartered in Israel and has a growing engineering team
The scale of the proposed deal was significant even by the standards of a booming AI sector. Anthropic, which has raised billions in funding from Amazon and Google among others, has the financial firepower to pursue large acquisitions. Yet the company has historically been cautious about M&A activity, preferring to build capabilities in-house. That caution may have ultimately prevailed here.
Anthropic's decision to step back from this deal signals that even well-funded AI labs are applying more scrutiny to billion-dollar acquisitions as the market matures.Industry analysts cited by Silicon Republic
What This Means for Anthropic's Strategy
Anthropic has been expanding aggressively across product lines, with recent moves into scientific and pharmaceutical applications alongside its core Claude offerings. The company launched Claude Science to target the pharma market, suggesting its priorities may lie more in vertical market expansion than in acquiring infrastructure-layer startups at steep valuations. Walking away from Decart could free up capital and management attention for those efforts.
The abandonment of the Decart deal also comes as Anthropic navigates a busy product roadmap. Reports emerged recently that the company has delayed the release of Claude Fable 5.1, hinting at internal resource constraints or quality considerations that may factor into broader strategic decisions. Whether the inference capabilities Anthropic sought from Decart will now be built internally or sourced elsewhere remains an open question.
For Decart, the outcome is a setback but not necessarily a fatal one. The startup's technology remains relevant, and other potential acquirers in the AI space, including larger cloud providers and model developers, could see value in what Decart has built. The company is likely to continue operating independently while weighing its options.
The broader takeaway is that dealmaking at the top of the AI market is proving more complicated than headline valuations suggest. Even when the strategic rationale appears clear, the gap between interest and completion can be substantial. Anthropic's retreat from this deal is a reminder that the current wave of AI consolidation will not move in a straight line.
